| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2010.34.4911 |
| P698 | PubMed publication ID | 21606427 |
| P2093 | author name string | Carmine Pinto | |
| Maria Chiara Tronconi | |||
| Stefano Cordio | |||
| Giovanni Silvano | |||
| Luca Cionini | |||
| Gerardo Rosati | |||
| Luca Boni | |||
| Sara Lonardi | |||
| Gabriele Luppi | |||
| Paola Rosetti | |||
| Maurizio Gallo | |||
| Andrea Bonetti | |||
| Anna Maria Bochicchio | |||
| Carlo Aschele | |||
| Salvatore Artale | |||
| Maria Emanuela Negru | |||
| Angiolo Tagliagambe | |||
| Domenico Cristiano Corsi | |||
| Germana Chiaulon | |||
| Giovanni Ambrosini | |||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase III clinical trial | Q42824827 |
| oxaliplatin | Q422327 | ||
| chemoradiotherapy | Q5090613 | ||
| P304 | page(s) | 2773-2780 | |
| P577 | publication date | 2011-05-23 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial | |
| P478 | volume | 29 |
| Q36211003 | 2011 update in gastrointestinal cancer therapeutics |
| Q40144624 | A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer. |
| Q37333621 | A Phase II Study of Additional Four-Week Chemotherapy With Capecitabine During the Resting Periods After Six-Week Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer |
| Q26739607 | A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer |
| Q33433227 | A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1) |
| Q35033392 | A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial). |
| Q87901096 | A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis |
| Q37724706 | A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis |
| Q36922653 | A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma |
| Q47126907 | A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer. |
| Q36742214 | A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial |
| Q35129364 | A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. |
| Q90471895 | A review of preoperative chemoradiotherapy for lower rectal cancer |
| Q33958747 | Abdominoperineal excision following preoperative radiotherapy for rectal cancer: unfavorable prognosis even with negative circumferential resection margin |
| Q42002475 | Accomplishments in 2008 in the adjuvant treatment of rectal cancer |
| Q43623679 | Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study |
| Q47376247 | Addition of oxaliplatin to neoadjuvant radiochemotherapy in MRI-defined T3, T4 or N+ rectal cancer: a randomized clinical trial. |
| Q47718910 | Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064). |
| Q54936297 | Additional 4-week capecitabine during the resting periods after 6-week neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: long-term oncologic outcomes. |
| Q26775099 | Adjuvant chemotherapy for rectal cancer: Is it needed? |
| Q52642667 | Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. |
| Q36025983 | Advances and challenges in treatment of locally advanced rectal cancer |
| Q55526826 | Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy. |
| Q42750637 | Advances in radiotherapy and targeted therapies for rectal cancer |
| Q53628384 | Advances in radiotherapy delivery for rectal cancer: a European perspective. |
| Q38222249 | Advances in the management of colorectal cancer: from biology to treatment |
| Q38237880 | Aims of combined modality therapy in rectal cancer (M0). |
| Q36824711 | An 80-gene set to predict response to preoperative chemoradiotherapy for rectal cancer by principle component analysis |
| Q37173767 | An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy |
| Q55602425 | Aneuploidy of chromosome 8 and mutation of circulating tumor cells predict pathologic complete response in the treatment of locally advanced rectal cancer. |
| Q50499549 | Applying nanotherapeutics to improve chemoradiotherapy treatment for cancer. |
| Q36287410 | Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer |
| Q38216007 | Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review. |
| Q38736426 | CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α. |
| Q33424898 | Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy? |
| Q33729092 | Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04 |
| Q46069155 | Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. |
| Q36216917 | Chemoradiotherapy with 5-fluorouracil/leucovorin, surgery and adjuvant chemotherapy for locally advanced rectal cancer. |
| Q34637479 | Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial |
| Q35820586 | Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery |
| Q36370649 | Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer |
| Q44483887 | Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer |
| Q37362938 | Clinical predictive factors of pathologic complete response in locally advanced rectal cancer. |
| Q41368254 | Clinicopathological outcomes of preoperative chemoradiotherapy using S-1 plus Irinotecan for T4 lower rectal cancer |
| Q57191694 | Colorectal cancer |
| Q24186443 | Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer |
| Q35475535 | Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial. |
| Q41696556 | Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis |
| Q37699754 | Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study |
| Q64228157 | Concomitant dose escalation with image-guided Tomotherapy in locally advanced mid-low rectal cancer: a single-center study |
| Q36112410 | Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study |
| Q46582003 | Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes |
| Q52653160 | Contemporary management of locally advanced rectal cancer: Resolving issues, controversies and shifting paradigms. |
| Q38691264 | Controversies in the multimodality management of locally advanced rectal cancer |
| Q28072948 | Current debate in the oncologic management of rectal cancer |
| Q35987944 | Current status of intensified neo-adjuvant systemic therapy in locally advanced rectal cancer |
| Q26824553 | Current treatment of rectal cancer adapted to the individual patient |
| Q54267061 | Definitive chemoradiotherapy with low-dose continuous 5-fluorouracil reduces hematological toxicity without compromising survival in esophageal squamous cell carcinoma patients. |
| Q49728422 | Difference in Tumor Area as a Predictor of a Pathological Complete Response for Patients With Locally Advanced Rectal Cancer |
| Q34927668 | Diffusion-weighted magnetic resonance application in response prediction before, during, and after neoadjuvant radiochemotherapy in primary rectal cancer carcinoma |
| Q38237878 | Do t3 rectal cancers always need radiochemotherapy? |
| Q42678047 | Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials |
| Q55241291 | Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer. |
| Q58761796 | Dosimetric analysis and comparison of reduced longitudinal cranial margins of VMAT-IMRT of rectal cancer |
| Q57758061 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making |
| Q38237882 | Early and late toxicity of radiotherapy for rectal cancer |
| Q35709494 | Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer |
| Q86500521 | Early rectal cancer: opening the door to change |
| Q36581449 | Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers |
| Q37733511 | Effect of Neoadjuvant Chemoradiotherapy on Locally Advanced Rectal Mucinous Adenocarcinoma: A Propensity Score-Matched Study. |
| Q36348179 | Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. |
| Q39267610 | Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy |
| Q33919715 | Effect of time interval between capecitabine intake and radiotherapy on local recurrence-free survival in preoperative chemoradiation for locally advanced rectal cancer |
| Q33749847 | Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis |
| Q45866914 | Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. |
| Q38618772 | Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis |
| Q35941120 | Evaluation of Selective Arterial Embolization Effect by Chitosan Micro-Hydrogels in Hindlimb Sarcoma Rodent Models Using Various Imaging Modalities |
| Q33411783 | Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer |
| Q36056754 | Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis |
| Q36419121 | Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study |
| Q37106318 | Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy |
| Q88551496 | Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt |
| Q35718282 | Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome |
| Q64085504 | How to Achieve a Higher Pathologic Complete Response in Patients With Locally Advanced Rectal Cancer Who Receive Preoperative Chemoradiation Therapy |
| Q35051918 | Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis |
| Q92360487 | Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer |
| Q34687101 | Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery |
| Q35779456 | Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy. |
| Q37190135 | Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy |
| Q90609131 | Impact of preoperative chemoradiotherapy using concurrent S-1 and CPT-11 on long-term clinical outcomes in locally advanced rectal cancer |
| Q36557598 | Implications for determining the optimal treatment for locally advanced rectal cancer in elderly patients aged 75 years and older. |
| Q35793914 | Implications for selecting local excision in locally advanced rectal cancer after preoperative chemoradiation |
| Q44896094 | Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. |
| Q40427841 | Inclusion of oxaliplatin in the multimodal treatment of locally advanced rectal cancer |
| Q64912431 | Increased Levels of Genomic Instability and Mutations in Homologous Recombination Genes in Locally Advanced Rectal Carcinomas. |
| Q58739885 | Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study |
| Q58751227 | Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - long-term results of phase II OIGIT-01 Trial |
| Q53005822 | Influence of position and radiation technique on organs at risk in radiotherapy of rectal cancer. |
| Q35001108 | Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications |
| Q50062237 | Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer : Impact on long-term outcome. Results of the phase II TAKO 05/ABCSG R‑02 trial |
| Q37295422 | Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial |
| Q36891772 | Is Preoperative Chemoradiotherapy Beneficial for Sphincter Preservation in Low-Lying Rectal Cancer Patients? |
| Q85623151 | Is the benefit of oxaliplatin in rectal cancer clinically relevant? |
| Q46413587 | Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy? |
| Q36300533 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer |
| Q36324953 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. |
| Q92776508 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer |
| Q55007170 | Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE). |
| Q48534064 | Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. |
| Q55023819 | Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer. |
| Q53172925 | Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. |
| Q90321434 | Long-term outcomes of neoadjuvant-synchronous S-1 plus radiotherapy for locally advanced rectal cancer: a multi-institutional prospective phase II study |
| Q34156692 | Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost |
| Q84225864 | Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience |
| Q61804233 | Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes |
| Q44584574 | MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer. |
| Q98158769 | Machine learning for predicting pathological complete response in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy |
| Q92730744 | Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer |
| Q36498946 | Management of a locally advanced rectal cancer in a patient who declined surgery |
| Q26823550 | Management of colorectal cancer |
| Q43584015 | Management of distal rectal cancer: results from a national survey |
| Q35029056 | Management of oligometastatic rectal cancer: is liver first? |
| Q33798353 | Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer |
| Q35623320 | Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer |
| Q84705111 | Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer |
| Q35920508 | Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future |
| Q38002470 | Multimodal treatment strategies for locally advanced rectal cancer |
| Q34289736 | Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. |
| Q35967483 | NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer |
| Q37408813 | Neo-adjuvant radiotherapy in rectal cancer |
| Q36848090 | Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial |
| Q37686375 | Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer |
| Q90304962 | Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial |
| Q49564068 | Neoadjuvant Treatment Strategies: Advanced Radiation Alternatives |
| Q34006430 | Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study |
| Q34359506 | Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer |
| Q61448004 | Neoadjuvant chemoradiation for locally advanced rectal cancer: a systematic review of the literature with network meta-analysis |
| Q35526713 | Neoadjuvant chemoradiotherapy for locally advanced rectal cancer: The debate continues |
| Q36153879 | Neoadjuvant chemotherapy followed by surgery versus surgery alone for colorectal cancer: meta-analysis of randomized controlled trials |
| Q33750803 | Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report |
| Q27003878 | Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer |
| Q44948248 | Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a single-institution experience. |
| Q43967231 | Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. |
| Q88761265 | Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study |
| Q34655838 | Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials |
| Q38064748 | Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated? |
| Q33697924 | Neoadjuvant therapy before surgical treatment |
| Q38546385 | Neoadjuvant treatment for locally advanced rectal cancer: a systematic review |
| Q34743672 | Neoadjuvant-intensified treatment for rectal cancer: time to change? |
| Q97525794 | Nomogram for predicting pathological complete response and tumor downstaging in patients with locally advanced rectal cancer on the basis of a randomized clinical trial |
| Q88795871 | Non-operative management of rectal cancer: understanding tumor biology |
| Q38645219 | Nonoperative management of rectal cancer |
| Q60927250 | Novelties in treatment of locally advanced rectal cancer |
| Q37715201 | On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery |
| Q38664897 | Optimal therapy for resectable rectal cancer |
| Q64274403 | Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer |
| Q37173570 | Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial |
| Q55381199 | Organ preservation in rectal cancer - Challenges and future strategies. |
| Q38338977 | Organ preservation in rectal cancer: have all questions been answered? |
| Q94487401 | Outcome measures in multimodal rectal cancer trials |
| Q26851986 | Outcome reporting in neoadjuvant surgical trials: a systematic review of the literature and proposals for new standards |
| Q34136267 | Overview of radiation therapy for treating rectal cancer |
| Q41572461 | Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial |
| Q51759783 | Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. |
| Q33417569 | Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial |
| Q34226859 | Oxaliplatin-based adjuvant chemotherapy without radiotherapy can improve the survival of locally-advanced rectal cancer |
| Q33432180 | Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials |
| Q37965616 | Oxaliplatin: a review of approved uses. |
| Q28280008 | Past, present, and future of radiotherapy for the benefit of patients |
| Q37322379 | Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis |
| Q38079162 | Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy |
| Q38425364 | Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study |
| Q53664136 | Pathological response of locally advanced rectal cancer to preoperative chemotherapy without pelvic irradiation. |
| Q36750960 | Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cance |
| Q55311004 | Phase I and II trial on infusional 5-fluorouracil and gefitinib in combination with preoperative radiotherapy in rectal cancer: 10-years median follow-up. |
| Q53179192 | Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. |
| Q64240620 | Phase I study of preoperative chemoradiotherapy with sequential oxaliplatin and irinotecan with S-1 for locally advanced rectal cancer |
| Q87477441 | Phase I trial of neoadjuvant preoperative chemotherapy with S-1, oxaliplatin, and bevacizumab plus radiation in patients with locally advanced rectal cancer |
| Q34737137 | Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer |
| Q37432618 | Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases |
| Q56357033 | Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03) |
| Q46876686 | Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer |
| Q90203248 | Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II) |
| Q35128016 | Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. |
| Q43488877 | Phase II study of preoperative chemoradiation with S-1 plus oxaliplatin in patients with locally advanced rectal cancer |
| Q51320998 | Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer. |
| Q34499632 | Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer |
| Q36921895 | Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer |
| Q38926899 | Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer |
| Q64903410 | Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy. |
| Q33441568 | Pre-operative hyperfractionated concurrent radiochemotherapy for locally advanced rectal cancers: a phase II clinical study |
| Q40899091 | Predictors for regional lymph node metastasis in T1 rectal cancer: a population-based SEER analysis |
| Q39800548 | Preoperative Chemoradiotherapy for Rectal Cancer in Patients Aged 75 Years and Older: Acute Toxicity, Compliance with Treatment, and Early Results |
| Q61801073 | Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer |
| Q34638544 | Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial |
| Q37417417 | Preoperative chemoradiotherapy in elderly patients with locally advanced rectal cancer |
| Q53611725 | Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial. |
| Q41498030 | Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study. |
| Q41395104 | Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial |
| Q57035666 | Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma |
| Q35814400 | Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy |
| Q48018828 | Prognostic value of pretreatment level of carcinoembryonic antigen on tumour downstaging and early occurring metastasis in locally advanced rectal cancer following neoadjuvant radiotherapy (30 Gy in 10 fractions). |
| Q39554319 | Progress in rectal cancer treatment. |
| Q41818560 | Prolonged neutropenia after neoadjuvant radiation therapy and chemotherapy using oxaliplatin and capecitabine for rectal cancer |
| Q58696703 | Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer |
| Q44197593 | Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). |
| Q53651597 | Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer. |
| Q36516962 | Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy |
| Q36368072 | Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma |
| Q26738806 | Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives |
| Q33797364 | Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology |
| Q38534726 | Recent advances in multidisciplinary approach for rectal cancer |
| Q90471871 | Recent advances in neoadjuvant chemoradiotherapy in locally advanced rectal cancer |
| Q63517624 | Rectal and Colon Cancer: Radiation Therapy Planning |
| Q84211615 | Rectal cancer--the times they are a-changing |
| Q42555130 | Rectal cancer: a review |
| Q38762762 | Redefining the Positive Circumferential Resection Margin by Incorporating Preoperative Chemoradiotherapy Treatment Response in Locally Advanced Rectal Cancer, a Multicenter Validation Study |
| Q50947717 | Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. |
| Q97905332 | Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q37475229 | SEOM Clinical Guideline of localized rectal cancer (2016). |
| Q48310789 | Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer. |
| Q37038486 | Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies |
| Q44226585 | Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified: analysis of local recurrence |
| Q51009768 | Short-course preoperative radiotherapy combined with chemotherapy, delayed surgery and local hyperthermia for rectal cancer: a phase II study. |
| Q53724796 | Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials. |
| Q37146188 | Smaller tumor size is associated with poor survival in T4b colon cancer |
| Q36014974 | Successful treatment of anal gland adenocarcinoma with combined modality therapy |
| Q38562040 | Surgeon perspectives on the use and effects of neoadjuvant chemoradiation in the treatment of rectal cancer: a comprehensive review of the literature |
| Q36121077 | Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial |
| Q38101653 | Surgical management and chemoradiotherapy of T1 rectal cancer |
| Q30235044 | Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer |
| Q57455374 | Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer |
| Q54114270 | Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. |
| Q38237877 | T4 rectal cancer: do we always need an exenteration? |
| Q37016664 | TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy |
| Q58276218 | Telomere-Specific Reverse Transcriptase (hTERT) and Cell-free RNA in Plasma as Predictors of Pathologic Tumor Response in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy |
| Q90586364 | The "addition" and "subtraction" of adjuvant chemotherapy for locally advanced colorectal cancer: where to go next? |
| Q49531454 | The Impact of Novel Radiation Treatment Techniques on Toxicity and Clinical Outcomes In Rectal Cancer |
| Q33776733 | The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer. |
| Q48308880 | The Role of Oxaliplatin in Chemoradiotherapy for Rectal Cancer. |
| Q36516445 | The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer |
| Q37913985 | The current landscape of locally advanced rectal cancer |
| Q34234935 | The emerging role of neoadjuvant chemotherapy for rectal cancer |
| Q57816131 | The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial |
| Q38359377 | The neoadjuvant treatment of rectal cancer: a review |
| Q34276823 | The role of capecitabine in locally advanced rectal cancer treatment: an update |
| Q37015715 | The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers |
| Q61809735 | The survival benefit of intensified full-dose XELOX chemotherapy concomitant to radiotherapy and then resting-period consolidation chemotherapy in locally advanced rectal cancer |
| Q34743494 | Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. |
| Q55331295 | Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients. |
| Q92189101 | Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy |
| Q37998384 | Toward the non-surgical management of locally advanced rectal cancer |
| Q94585888 | Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study |
| Q36351882 | Treatment of locally advanced rectal cancer: controversies and questions |
| Q38170032 | Treatment of stage II-III rectal cancer patients |
| Q41847005 | Tumor-based screening for hereditary nonpolyposis colorectal cancer: does age-based selection optimize yield? |
| Q91674081 | UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan |
| Q36403031 | Update and debate issues in surgical treatment of middle and low rectal cancer |
| Q92996657 | Variability of Oxaliplatin-Induced Neuropathic Pain Symptoms in Each Cycle and Its Implications on the Management of Colorectal Cancer Patients: A Retrospective Study in South Western Sydney Local Health District Hospitals, Sydney, Australia |
| Q55077052 | Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer. |
| Q51049865 | What is most relevant in preoperative rectal cancer chemoradiotherapy - the chemotherapy, the radiation dose or the timing to surgery? |
| Q46504181 | Which way is forward in the treatment of rectal cancer? |
| Q36562267 | YpT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer |
| Q82086751 | [Diagnosis and treatment of rectal cancer] |
| Q84197336 | [Radiotherapy of rectal cancer] |
| Q54678569 | [Radiotherapy-associated morbidity and mortality in rectal surgery]. |
| Q98386357 | γ-H2AX as a potential indicator of radiosensitivity in colorectal cancer cells |
Search more.